Two-dimensional difference gel electrophoresis (DIGE) analysis of sera from visceral leishmaniasis patients

Clinical Proteomics

Volumn 8, Issue 1, 2011, Pages

  Rukmangadachar, Lokesh A ^a   Kataria, Jitender ^a   Hariprasad, Gururao ^a   Samantaray, Jyotish C ^a   Srinivasan, Alagiri ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; OROSOMUCOID; PREALBUMIN; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C1S INHIBITOR; RETINOL BINDING PROTEIN;

ADULT; AGE DISTRIBUTION; ARTICLE; BANGLADESH; BRAZIL; CLINICAL ARTICLE; CONTROLLED STUDY; DEVELOPING COUNTRY; DOWN REGULATION; ENDEMIC DISEASE; ETHIOPIA; FEMALE; HUMAN; IMAGE ANALYSIS; IMMUNE DEFICIENCY; INDIA; MALE; NEPAL; NUCLEOTIDE SEQUENCE; PHLEBOTOMUS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SERUM; SUDAN; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION; VISCERAL LEISHMANIASIS; WESTERN BLOTTING; COHORT ANALYSIS; INTERMETHOD COMPARISON; PROTEIN DEPLETION; PROTEOMICS; QUANTITATIVE ANALYSIS; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS;

PHLEBOTOMINAE;

EID: 84860617698     PISSN: 15426416     EISSN: 15590275     Source Type: Journal    
DOI: 10.1186/1559-0275-8-4     Document Type: Article

References (32)

1. Leishmaniasis: current situation and new perspectives. Desjeux P, Comp Immunol Microbiol Infect Dis 2004 27 305 18 10.1016/j.cimid.2004.03.004 15225981 (Pubitemid 38842803)
2. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Chappuis F, Sundar S, Hailu A, et al. Nat Rev Microbiol 2005 5 873 82 (Pubitemid 47578388)
3. Enzyme-linked immunosorbent assay for recombinant K39 antigen in diagnosis and prognosis of Indian visceral leishmaniasis. Kumar R, Pai K, Pathak K, Sundar S, Clin Diagn Lab Immunol 2007 8 1220 24
4. Molecular Diagnosis of Leishmaniasis: Current Status and Future Applications. Reithinger R, Dujardin JC, J Clin Microbiol 2007 45 21 25 10.1128/JCM.02029-06 17093038 (Pubitemid 46106401)
5. Human body fluid proteome analysis. Hu S, Loo JA, Wong DT, Proteomics 2006 6 6326 53 10.1002/pmic.200600284 17083142 (Pubitemid 44935518)
6. Electrophoretic differential serum protein pattern in kala-azar. Shanker A, British Medical journal 1959 9 1221 23
7. Mapping the antigenicity of the parasites in Leishmania donovani infection byproteome serology. Forgber M, Basu R, Roychoudhury K, et al. PLoS One 2006 1 40 10.1371/journal.pone.0000040 17183669
8. Differences among techniques for high-abundant protein depletion. Zolotarjova N, Martosella J, Nicol G, Bailey J, Boyes BE, Barrett WC, Proteomics 2005 5 3304 13 10.1002/pmic.200402021 16052628 (Pubitemid 41192037)
9. Efficient and specific removal of albumin from human serum samples. Steel LF, Trotter MG, Nakajima PB, Mattu TS, Gonye G, Block T, Mol Cell Proteomics 2003 2 262 70 12754305
10. Statistical analysis of the experimental variation in the proteomic characterization of human plasma by two-dimensional difference gel electrophoresis. Corzett TH, Fodor IK, Choi MW, et al. J Proteome Res 2006 5 2611 19 10.1021/pr060100p 17022632 (Pubitemid 44595163)
11. A novel and accurate diagnostic test for human African trypanosomiasis. Papadopoulos MC, Abel PM, Agranoff D, et al. Lancet 2004 363 1358 63 10.1016/S0140-6736(04)16046-7 15110493 (Pubitemid 38529875)
12. Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum. Agranoff Fernandez-Reyes D, Papadopoulos MC, Rojas SA, Herbster M, Loosemore A, Lancet 2006 368 1012 21 10.1016/S0140-6736(06)69342-2 16980117 (Pubitemid 44353670)
13. Serum proteome of leprosy patients undergoing erythema nodosum leprosum reaction: regulation of expression of the isoforms of haptoglobin. Gupta N, Shankernarayan NP, Dharmalingam K, J Proteome Res 2006 6 3669 79 (Pubitemid 47522756)
14. Alpha 1-acid glycoprotein potentiates lipopolysaccharide-induced secretion of interleukin-1 beta, interleukin-6 and tumor necrosis factor-alpha by human monocytes and alveolar and peritoneal macrophages. Boutten A, Dehoux M, Deschenes M, Rouzeau JD, Bories PN, Durand G, Eur J Immunol 1992 22 2687 95 10.1002/eji.1830221032 1396973
15. Protection by alpha 1-acid glycoprotein against tumor necrosis factor-induced lethality. Libert C, Brouckaert P, Fiers W, J Exp Med 1994 180 1571 75 10.1084/jem.180.4.1571 7931089
16. Acute phase protein concentrations predict parasite clearance rate during therapy for visceral leishmaniasis. Wasunna KM, Raynes JG, Were JB, et al. Trans R Soc Trop Med Hyg 1995 89 678 81 10.1016/0035-9203(95)90442-5 8594695 (Pubitemid 26016362)
17. Biological activities of c1 inhibitor. Davis AE III, Mejia P, Lu F, Mol Immunol 2008 45 4057 63 10.1016/j.molimm.2008.06.028 18674818
18. Complement 1 inhibitor is a regulator of the alternative complement pathway. Jiang H, Wagner E, Zhang H, Frank MM, J Exp Med 2001 194 1609 16 10.1084/jem.194.11.1609 11733575 (Pubitemid 33126811)
19. Anti-inflammatory effects of C1-Inhibitor in porcine and human whole blood are independent of its protease inhibition activity. Thorgersen EB, Ludviksen JK, Lambris JD, Sfyroera G, Nielsen EW, Mollnes TE, Innate Immun 2010 16 254 64 10.1177/1753425909340420 19710096
20. Variable degree of alternative complement pathway-mediated hemolysis in Indian visceral leishmaniasis induced by differential expression of 9-O-acetylated sialoglycans. Chava AK, Chatterjee M, Sharma V, Sundar S, Mandal C, J Infect Dis 2004 189 1257 64 10.1086/382752 15031795 (Pubitemid 38457251)
21. C1-inhibitor: an anti-inflammatory reagent with therapeutic potential. Kirschfink M, Mollnes TE, Expert Opin Pharmacother 2001 2 1073 83 10.1517/14656566.2.7.1073 11583058 (Pubitemid 32633709)
22. C1, MBL MASPs and C1-inhibitor: novel approaches for targeting complement-mediated inflammation. Beinrohr L, Dobá J, Závodszky P, Gál P, Trends Mol Med 2008 14 511 21 10.1016/j.molmed.2008.09.009 18977695
23. Clinical indications for plasma protein assays: transthyretin (prealbumin) in inflammation and malnutrition. Johnson AM, Merlini G, Sheldon J, Ichihara K, Clin Chem Lab Med 2007 45 419 26 10.1515/CCLM.2007.051 17378745 (Pubitemid 46480890)
24. Clinical and nutritional aspects of changes in acute-phase proteins during inflammation. Fleck A, Proc Nutr Soc 1989 48 347 54 10.1079/PNS19890050 2482490
25. Study of protein profile in the visceral leishmaniasis. Bouree P, Botterel F, Lancon A, J Egypt Soc Parasitol 2000 30 885 93 11198386
26. Transthyretin is an inhibitor of monocyte and endothelial cell interleukin-1 production. Borish L, King MS, Mascali JJ, Johnson S, Coll B, Rosenwasser LJ, Inflammation 1992 16 471 84 10.1007/BF00918973 1385328
27. The structure of human retinol-binding protein (RBP) with its carrier protein transthyretin reveals an interaction with the carboxy terminus of RBP. Naylor HM, Newcomer ME, Biochemistry 1999 38 2647 53 10.1021/bi982291i 10052934 (Pubitemid 29122323)
28. Association of nutritional status with the response to infection with Leishmania chagasi. Maciel BL, Lacerda HG, Queiroz JW, et al. Am J Trop Med Hyg 2008 79 591 98 18840750
29. Regulation of metabolism of retinol-binding protein by vitamin A status in children with biliary atresia. Mourey MS, Siegenthaler G, Amédée-Manesme O, Am J Clin Nutr 1990 51 638 43 2321569
30. Plasma lipoproteins in infantile visceral leishmaniasis: deficiency of apolipoproteins A-I and A-II. Bekaert D, Kallel R, Bouma ME, et al. Clin Chim Acta 1989 184 181 91 10.1016/0009-8981(89)90288-X 2514050 (Pubitemid 19238987)
31. Structural models of human apolipoprotein A-I: a critical analysis and review. Anantharamaiah GM, Engler JA, Borhani DW, Biochim Biophys Acta 2001 1531 4 46 11278170 (Pubitemid 32241248)
32. Apolipoprotein A-I inhibits the production of interleukin-1 and tumor necrosis factor- by blocking contact-mediated activation of monocytes by T lymphocytes. Hyka N, Dayer J, Modoux C, et al. Blood 2001 97 2381 89 10.1182/blood.V97.8.2381 11290601 (Pubitemid 32291485)